<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="785">
  <stage>Registered</stage>
  <submitdate>23/09/2005</submitdate>
  <approvaldate>11/11/2005</approvaldate>
  <actrnumber>ACTRN12605000739617</actrnumber>
  <trial_identification>
    <studytitle>Microvascular Complications in Patients with Type 1 Diabetes</studytitle>
    <scientifictitle>Microvascular complications in patients with Type 1 Diabetes. To determine the relationship between abnormalities of autonomic function and markers of microvascular disease and cardiovascular risk in patients with Type 1 Diabetes.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Type 1 diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Type 1 diabetes is associated with the development of microvascular complications including nephropathy, retinopathy, peripheral and autonomic neuropathies. Diabetic autonomic neuropathy is a serious yet under-recognised complication. It is thought that the presence of autonomic neuropathy heralds more widespread implications both in terms of cardiovascular risk and its close relationship to other microvascular complications.
This study hopes to determine the relationship between autonomic neuropathy, markers of microvascular disease and cardiovascular risk.
This cross-sectional analysis of the study population at a single site will consist of an initial visit when the patient will present to the clinic in a fasting state. At this visit the patient will have the following procedures:
1. Two measures of autonomic function (pupilometry and R-R variability).
2. Pulse wave analysis
3. HbA1c, EUC, B-type natriuretic peptide (BNP)  and lipid levels
4. Retinal photography
5. Neurothesiometry
6. Electronic Blood pressure
7. Fitting of a 24 hour ambulatory blood pressure monitor
8. A timed overnight urine measurement of Albumin Excretion Rate
9. A 24 hour urine collection to measure Creatinine Clearance
10. Ankle Brachial Index measurement
The patient will be asked to return in 12 months time and have a repeat of all the procedures.</interventions>
    <comparator />
    <control />
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. To determine the prevalence of autonomic neuropathy by two different techniques in patients with Type 1 Diabetes of short and longer duration.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. To determine the characteristics of patients with and without autonomic neuropathy including the prevalence of other microvascular complications of diabetes (retinopathy/nephropathy/neuropathy) in the groups.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>3. To determine the prevalence of non-dipping of blood pressure in patients with and without autonomic neuropathy (as determined by pupillometry or R-R variability).</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>4. To determine the effect of non-dipping on the vasculature according to pulse-wave analysis, and on renal function as assessed by creatinine clearance and the presence of microalbuminuria.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>5. To determine longitudinal development (at least 12 months) of markers of microvascular disease in patients with baseline autonomic neuropathy but no baseline microvascular disease.</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>6. To determine the B-type natriuretic peptide (BNP) level which is a polypeptide produced by the cardiac ventricles and has been found to be sensitive and a specific marker of left ventricular dysfunction.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. HbA1c</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Lipids</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Fasting glucose</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients who have been informed of the study procedure and have given written informed consent.2. Unequivocal diagnosis of Type 1 diabetes mellitus.</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients who are unwilling or unable to attend the clinic on two consecutive days.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney Diabetes Clinical Research Unit, Royal North Shore Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Sydney Diabetes Clinical Research Unit, Royal North Shore Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney Diabetes Clinical Research Unit</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal North Shore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Anne McCormack</name>
      <address>Endocrinology
Royal North Shore Hospital
Level 3
Main Block
St Leonards NSW 2065</address>
      <phone>+61 2 99268388</phone>
      <fax>+61 2 94395181</fax>
      <email>mccormackann@optushome.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Caitlin Scott</name>
      <address>Sydney Diabetes Clinical Research Unit
Royal North Shore Hospital
Level 3
Main Block
St Leonards NSW 2065</address>
      <phone>+61 2 99266879</phone>
      <fax>+61 2 94395181</fax>
      <email>cscott@nsccahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>